Pramiracetam for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Pramiracetam for Health & Longevity

Created on 07/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A fat-soluble lab-made compound that helps brain cells take up choline, the building block for a key memory messenger. Its most consistent reported effect is better recall in people who already have memory problems from brain injury or aging. For healthy adults, benefits to focus and learning remain plausible but unproven. Kidney function most shapes how the body handles it. (Full Review)

Protocol

Standard Amount
1,200 mg/day
400 mg three times daily or 600 mg twice daily
Timing
Morning & early afternoon
Split dosing to maintain steadier levels; avoids sleep disruption
Pair With Choline
Choline donor each dose
Supports acetylcholine synthesis and limits headache
Time to effect
Memory
Weeks
Memory benefits in clinical studies emerged over weeks of consistent use
Focus & Processing
Within hours
Acute effects, if present, reported within hours of a dose
Fair Trial
Several weeks
A fair trial spans several weeks of consistent use

Benefits

Contraindications
  • Significant kidney impairment (eGFR below ~30–60 mL/min/1.73m²)
  • Pregnancy or breastfeeding
  • Children and adolescents
  • Uncontrolled epilepsy
    •
Key Interactions
  • Choline donors (alpha-GPC, CDP-choline/citicoline, choline bitartrate)
  • Other racetams and cholinergics (piracetam, aniracetam, oxiracetam, centrophenoxine)
  • Anticholinergic drugs (scopolamine, oxybutynin, diphenhydramine, tricyclic antidepressants)
  • Over-the-counter agents (sedating antihistamines, caffeine)
  • Stimulants (amphetamine, methylphenidate, modafinil, caffeine)
  • Renally cleared drugs (metformin, gabapentin, methotrexate, lithium)
  • Alcohol
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Headache; gastrointestinal discomfort; nervousness, insomnia, and fatigue
    •
  • Speculative: Unknown long-term safety; theoretical overstimulation of brain signaling
    •

Monitoring

Marker Target Why
Estimated kidney filtration (eGFR) > 90 mL/min/1.73m² Governs drug clearance and exposure
Serum creatinine 0.7–1.1 mg/dL Confirms kidney clearance capacity
Blood urea nitrogen (BUN) 10–16 mg/dL Secondary kidney and hydration marker
Homocysteine < 7 µmol/L Reflects B-vitamin and methylation status supporting choline pathways

Cadence: Baseline before starting; kidney markers reviewed roughly every 6–12 months with extended use

Qualitative Assessment

  • Noticeable, repeatable improvement in memory or recall during a defined trial period
  • Sharper focus and faster mental processing on demanding cognitive tasks
  • Absence of headache, jitteriness, or sleep disruption at the chosen dose
  • A clear difference when pausing and restarting, rather than a vague or placebo-like impression
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.